Organization (Other)
Statens Serum Institut
ClinicalTrials.gov lists Statens Serum Institut as lead sponsor of 28 trials. It has 21 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Statens Serum Institut: 28 lead-sponsored trials and 1 legal-entity registration.
Disease areas (83)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Tuberculosis | 24 |
| Obesity | 5 |
| Malaria | 4 |
| Poliomyelitis | 4 |
| HIV Infections | 3 |
Showing 5 of 83 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 4 |
| 2016 | 7 |
Showing 10 of 26 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (21)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| BCG | Tuberculosis | Phase 1 | 1 |
| H107e/CAF®10b - low adjuvant dose | Tuberculosis | Phase 1 | 1 |
| Low dose intranasal H107e | Tuberculosis | Phase 1 | 1 |
| H107e/CAF®10b - full adjuvant dose | Tuberculosis | Phase 1 | 1 |
| Intranasal H107e | Tuberculosis | Phase 1 | 1 |
Showing 5 of 21 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Prevenar 13 | 1 |
| PNEUMOVAX | 1 |
| Metronidazole | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 1 of 3 on time (n=3) |
Journals published in (113)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Vaccine | 20 |
| The American journal of clinical nutrition | 10 |
| BMJ (Clinical research ed.) | 8 |
| The Journal of infectious diseases | 6 |
| The Lancet. Infectious diseases | 6 |
Showing 5 of 113 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 54 | 2 | 2025-10-14 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Statens Serum Institut | Copenhagen S, DK | EMA, Health Canada |
Organization relationships (35)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Gates Foundation | Co sponsors trial with | 5 |
| Hvidovre University Hospital | Co sponsors trial with | 4 |
| Larix A/S | Co sponsors trial with | 4 |
| Copenhagen University Hospital, Rigshospitalet | Co sponsors trial with | 3 |
| AJ Vaccines A/S | Co sponsors trial with | 3 |
Showing 5 of 35 relationships.
Latest dated events (140)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-11-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-06-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 140 events.
Biomarker capability evidence (74)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BCL2 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 74 evidence rows.
Biomarkers this organization publishes on (520)
Shown in this order: most publications first.
Showing 5 of 520 biomarkers.
On Scientist.com
Statens Serum Institut is listed as a research supplier in the Scientist.com network.
Service areas
Statens Serum Institut (SSI) offers in vivo and in vitro infectious disease model, pharmacokinetics, and manufacturing services.
- Website
- www.ssi.dk/English
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Statens Serum Institute (SSI) on Scientist.com
For prices, more details, or to contact Statens Serum Institute (SSI), visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.